Supplementary Table 5. MMC placement subanalysis: Concentration and time of exposure of MMC and concomitant cataract surgery by consecutive patient groups (PP population)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Analysis |  | Group 1 (*n* = 36) | Group 2 (*n* = 25) | Overall(N = 61) |
| MMC Concentration Used | 0.2 mg/mL | 6 (16.7%) | 23 (92.0%) | 29 (47.5%) |
|  | 0.4 mg/mL | 30 (83.3%) | 2 (8.0%) | 32 (52.5%) |
| Time of Exposure to MMC | 2 minutes | 10 (27.8%) | 25 (100.0%) | 35 (57.4%) |
|  | 3 minutes | 26 (72.2%) | 0 | 26 (42.6%) |
| MMC Concentration Used by Time of Exposure | 0.2 mg/mL for 2 minutes | 6 (16.7%) | 23 (92.0%) | 29 (47.5%) |
| 0.2 mg/mL for 3 minutes | 0 | 0 | 0 |
|  | 0.4 mg/mL for 2 minutes | 4 (11.1%) | 2 (8.0%) | 6 (9.8%) |
|  | 0.4 mg/mL for 3 minutes | 26 (72.2%) | 0 | 26 (42.6%) |
|  |  |  |  |  |
| Surgery in combination with cataract surgery | Yes | 2 (5.6%) | 13 (52.0%) | 15 (24.6%) |
| No | 34 (94.4%) | 12 (48.0%) | 46 (75.4%) |
|  |  |  |  |  |
| Surgery in combination with cataract surgery by MMC concentration | 0.2 mg/mL | 0 | 11 (84.6%) | 11 (73.3%) |
| 0.4 mg/mL | 2 (100.0%) | 2 (15.4%) | 4 (26.7%) |
|  |  |  |  |

Group 1 was defined as the first 36 patients to undergo MicroShunt implantation, and Group 2 as the following 25 patients to receive MicroShunt. MMC concentration and time of exposure was chosen on a case-by-case basis by patient age, disease progression, and other baseline characteristics. Due to the adaptive nature of the study, MMC usage in Group 2 was also guided by earlier cases.